SAPHIR
SAPHIR was a Phase 2A Multicentre, Randomised, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Study of PQ912 in Subjects With Early Alzheimer’s Disease.
The aim of this study was to evaluate the safety, tolerability and preliminary efficacy of PQ912 in subjects with Mild Cognitive Impairment (MCI) due to Alzheimer’s Disease (AD) or mild dementia due to AD.
24 SITES
120 PATIENTS
STATUS: FINISHED
PUBLICATIONS
Emerging amyloid and tau targeting treatments for Alzheimer’s disease
Khan, Ayesha, Anne Corbett, and Clive Ballard. “Emerging amyloid and tau targeting treatments for Alzheimer’s disease.” Expert Review of Neurotherapeutics just-accepted (2017).
Stay in touch
